Shengting Li, Vice President of Clinical Development at Cullinan Therapeutics, shared a post on LinkedIn about a paper by Bonan Chen et al. published in Molecular Cancer:
“Antibody-drug conjugates (ADCs) efficacy across hematologic and solid malignancies. However, challenges persist. Emerging innovations such as bispecific ADCs, immune-stimulatory payloads, AI-guided design, and nanotechnology-enhanced delivery are reshaping the ADC landscape, necessity of diagnostic precision and rational combination strategies, and the future direction of next-generation ADC therapeutics.”
Title: Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions
Authors: Bonan Chen, Xiaohong Zheng, Jialin Wu, Guoming Chen, Jun Yu, Yi Xu, William K. K. Wu, Gary M. K. Tse, Ka Fai To, Wei Kang
You can read the Full Article in Molecular Cancer.
More posts on ADCs on OncoDaily.